NovoCure Limited - Ordinary Shares (NVCR)
13.15
+0.04 (0.31%)
NASDAQ · Last Trade: Oct 30th, 7:42 PM EDT
News & Press Releases
NovoCure Q3 Earnings Call Highlightsmarketbeat.com
NovoCure (NASDAQ:NVCR) reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped lift active patient counts to a record level. The company also raised its full-year revenue and adjus
Via MarketBeat · October 29, 2026
NovoCure (NVCR) Q3 2026 Earnings Call Transcriptfool.com
Record revenue and positive adjusted EBITDA in four years mark profitability shift.
Via The Motley Fool · October 29, 2026
Novocure (NASDAQ:NVCR) Q3 Results Beat Estimates as Raised Outlook Lifts Stockchartmill.com
Via Chartmill · October 29, 2026
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
Novocure (Nasdaq: NVCR) today reported financial results for the third quarter that ended September 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
By Novocure · Via Business Wire · October 29, 2026
Novocure (NASDAQ:NVCR) Rallies 13% on Earnings Beat as High Growth Stock Nears Profitabilitychartmill.com
Via Chartmill · July 23, 2026
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure’s Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem’s investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, to treat locally advanced pancreatic cancer.
By Novocure · Via Business Wire · October 28, 2026
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.
By Novocure · Via Business Wire · October 1, 2026
Novocure to Report Third Quarter 2026 Financial Results
Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open.
By Novocure · Via Business Wire · October 1, 2026
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Evenmarketbeat.com
NovoCure (NASDAQ:NVCR) outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference.
Chief Executive Officer Frank Leonard said the company, founded more th
Via MarketBeat · September 18, 2026
Novocure Announces Upcoming Investor Events
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.
By Novocure · Via Business Wire · September 2, 2026
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Gainers NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regular session. The market value of their outstanding shares is at $1.8 billion. The company's, Q2 earnings came out
Via Benzinga · July 23, 2026
The market is filled with gapping stocks in Thursday's session.chartmill.com
Via Chartmill · July 23, 2026
NovoCure Q2 Earnings Call Highlightsmarketbeat.com
NovoCure (NASDAQ:NVCR) reported record second-quarter 2026 net revenue and active patient levels, with management pointing to growth across its approved products and improved expense discipline as it raised full-year revenue and adjusted EBITDA guidance.
Executive Chairman William Doyle said the qu
Via MarketBeat · July 23, 2026
Transcript: NovoCure Q2 2026 Earnings Conference Callbenzinga.com
NovoCure (NASDAQ:NVCR) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Via Benzinga · July 23, 2026
Novocure Reports Second Quarter 2026 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
By Novocure · Via Business Wire · July 23, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 14, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 7, 2026
Novocure to Report Second Quarter 2026 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open.
By Novocure · Via Business Wire · July 1, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · June 30, 2026
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
Novocure (NASDAQ: NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations.
By Novocure · Via Business Wire · June 30, 2026
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?fool.com
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.
Via The Motley Fool · June 24, 2026
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?fool.com
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
Via The Motley Fool · June 22, 2026
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or “the Company”) (NASDAQ: NVCR) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · June 20, 2026
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?fool.com
Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.
Via The Motley Fool · June 19, 2026
Thursday's session: gap up and gap down stockschartmill.com
Via Chartmill · June 18, 2026